Clinical trial
A Randomized 4-week Phase IIa Trial Evaluating the Efficacy, Safety, and Tolerability of GRT6005, a New Centrally Acting Analgesic, in Subjects With Pain Due to Diabetic Polyneuropathy.
NCT01347671 is registered in ClinicalTrials.gov with Tris Pharma, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized 4-week Phase IIa Trial Evaluating the Efficacy, Safety, and Tolerability of GRT6005, a New Centrally Acting Analgesic, in Subjects With Pain Due to Diabetic Polyneuropathy.
- Lead sponsor
- Tris Pharma, Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- May 31, 2011
- Completion date
- January 31, 2012
- Enrollment
- 189 (actual)
- Sites
- 22
Conditions
As the registry lists them; a condition with its own page is linked.